Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 December 2011

Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin

Tatsuya FujinoABCDE, Makoto NakamutaABDG, Yoko AoyagiB, Motoyuki KohjimaB, Takeaki SatohB, Mika FukudaB, Hiromi IshibashiB, Hiroshi YatsuhashiABD, Munechika EnjojiDEFG

DOI: 10.12659/MSM.882127

Med Sci Monit 2011; 17(12): CR687-691

Abstract

Background: We aimed to assess differences in early viral dynamics following treatment with either peg-IFNalpha2a or peg-IFNalpha2b in combination with ribavirin in patients with chronic genotype 1b HCV infection.
Material/Methods: Sixty-one patients in the peg-IFNalpha2a + ribavirin treatment (group alpha2a) and 88 patients in the peg-IFNalpha2b + ribavirin treatment (group alpha2b) were retrospectively analyzed. The early dynamics of HCV RNA over 12 weeks were evaluated. Sustained virological response (SVR) was defined as undetectable HCV RNA at week 24 after end of therapy. First- (day 0–1) and second-phase (day 1–28) viral decline rates were calculated in accordance with theoretical formulae.
Results: Baseline HCV RNA concentrations were almost similar between the 2 groups. In group alpha2a, viral decline was significantly greater than in group alpha2b at weeks 4, 8, and 12. In group alpha2a, viral decline was significantly greater in SVR patients than in non-SVR patients at week 2, whereas significantly greater viral decline in SVR patients was found during weeks 1–12 in group alpha2b. The first-phase viral decline rate was significantly larger in group alpha2a than in group alpha2b (1.31±0.84 vs. 0.70±0.97 log IU/mL/day; p<0.0001). Within SVR patients, first-phase viral decline rate was significantly larger in group α2a compared with group alpha2b (1.45±0.85 vs. 0.78±1.0 log IU/mL/day; p<0.0001). Second-phase viral decline rate was comparable between the groups.
Conclusions: Peg-IFNalpha2a showed earlier viral decline than peg-IFNalpha2b and the difference was obvious, especially in the first-phase viral decline.

Keywords: Models, Biological, Polyethylene Glycols - therapeutic use, Kinetics, Interferon-alpha - therapeutic use, Hepatitis C, Chronic - virology, Hepacivirus - physiology, Genotype, Drug Therapy, Combination, Antiviral Agents - therapeutic use, RNA, Viral - blood, Recombinant Proteins - therapeutic use, ribavirin, Viremia - virology

0 Comments

Editorial

01 November 2021 : Editorial  

Editorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems During the COVID-19 Pandemic?

Dinah V. Parums
Scientific Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.935299

Med Sci Monit 2022; 28:e935299

SARS-CoV-2/COVID-19

26 November 2021 : Editorial  

Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19

Med Sci Monit In Press; DOI: 10.12659/MSM.935624  

08 November 2021 : Database Analysis  

Virtual Screening and Molecular Docking to Study the Mechanism of Chinese Medicines in the Treatment of Cor...

Med Sci Monit In Press; DOI: 10.12659/MSM.934102  

25 November 2021 : Clinical Research  

Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumato...

Med Sci Monit 2021; 27:e934267

In Press

29 Nov 2021 : Database Analysis  

Integrated Analysis of Angiogenesis-Mediated Tumor Immune Microenvironment Pattern in Hepatocellular Carcin...

Med Sci Monit In Press; DOI: 10.12659/MSM.934937  

26 Nov 2021 : Clinical Research  

Serum Uric Acid Levels in Relation to Atrial Fibrillation: A Case-Control Study

Med Sci Monit In Press; DOI: 10.12659/MSM.934007  

26 Nov 2021 : Database Analysis  

Network Pharmacology Integrated Molecular Docking Revealed the Mechanism of Jianpi Yiqi Taohua Decoction Ag...

Med Sci Monit In Press; DOI: 10.12659/MSM.933537  

26 Nov 2021 : Editorial  

Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19

Med Sci Monit In Press; DOI: 10.12659/MSM.935624  

Most Viewed Current Articles

20 Mar 2020 : Clinical Research  

Social Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...

DOI :10.12659/MSM.923921

Med Sci Monit 2020; 26:e923921

15 Apr 2020 : Clinical Research  

Psychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...

DOI :10.12659/MSM.924171

Med Sci Monit 2020; 26:e924171

05 May 2020 : Review article  

An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development

DOI :10.12659/MSM.924700

Med Sci Monit 2020; 26:e924700

26 Apr 2020 : Clinical Research  

Comparison of Prevalence and Associated Factors of Anxiety and Depression Among People Affected by versus P...

DOI :10.12659/MSM.924609

Med Sci Monit 2020; 26:e924609

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750